Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

Nature Medicine

Volumn 9, Issue 6, 2003, Pages 762-767

  Bézard, Erwan ^a   Ferry, Sandrine ^b   Mach, Ulrich ^c   Stark, Holger ^c   Leriche, Ludovic ^b   Boraud, Thomas ^a   Gross, Christian ^a   Sokoloff, Pierre ^b  

^a CNRS   (France)

^b INSERM   (France)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; BENSERAZIDE PLUS LEVODOPA; BP 897; DIZOCILPINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; N [4 (1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL)BUTYL] 3 PHENYLACRYLAMIDE; NAFADOTRIDE; ST 198; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; DYSKINESIA; FEMALE; INVOLUNTARY MOVEMENT; MONKEY; MOUSE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TREATMENT OUTCOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACRYLAMIDES; ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HAPLORHINI; HUMANS; ISOQUINOLINES; LEVODOPA; MOLECULAR STRUCTURE; MOTOR ACTIVITY; MPTP POISONING; NAPHTHALENES; NEOSTRIATUM; PIPERAZINES; PYRROLIDINES; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

ANIMALIA; PARKINSONIA;

EID: 0038579160     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm875     Document Type: Article

References (33)

1. Carlsson, A. A paradigm shift in brain research. Science 294, 1021-1024 (2001).
2. Pulverenti, L. & Koob, G.E Being partial to psychostimulant addiction therapy. Trends Pharmacol. Sci. 23, 151-153 (2002).
3. Jenner, P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58 (suppl. 1), S1-S8 (2002).
4. Hornykiewicz, O. Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinsonkranken Menschen. Wien. Klin. Wochenschr. 75, 309-312 (1963).
5. Bezard, E., Brotchie, J.M. & Gross, C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577-587 (2001).
6. 3 receptor expression indicates the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA 92, 1719-1723 (1995).
7. 3 receptor expression and triggers behavioural sensitization. Nature 411, 86-89 (2001).
8. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA 94, 3363-3367 (1997).
9. Cotzias, G.C., Papavasiliou, P.S. & Gellene, R. Modification of Parkinsonism-chronic treatment with L-dopa. New Eng. J. Med. 280, 337-345 (1969).
10. Burns, R.S. et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550 (1983).
11. Pearce, R.K., Jackson, M., Smith, L., Jenner, P. & Marsden, C.D. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrixjacchus). Mov. Disord. 10, 731-740 (1995).
12. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10, 2565-2573 (1998).
13. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98, 263-273 (2000).
14. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13, 788-797 (1998).
15. 3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 214, 75-78 (1996).
16. 3 receptor agonist. Nature 400, 371-375 (1999).
17. Grondin, R., Tahar, A.H., Doan, V.D., Ladure, P. & Bedard, P.J. Noradrenoceptor antagonism with idazoxan improves L -dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedebergs Arch. Pharmacol. 361, 181-186 (2000).
18. 3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275, 1239-1246 (1995).
19. 2 dopamine receptors by 7-OH-DPAT. Synapse 24, 60-64 (1996).
20. 3-receptors: receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293, 1048-1062 (2000).
21. 3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294, 1154-1165 (2000).
22. 3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur. J. Pharmacol. [Mol. Pharmacol. Sect.] 268, 129-139 (1994).
23. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779, 58-74 (1998).
24. Boraud, T., Bezard, E., Bioulac, B. & Gross, C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124, 546-557 (2001).
25. 3 receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. USA 93, 1945-1949 (1996).
26. 2 receptors. Nature 377, 424-428.
27. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432 (1990).
28. Rascol, O. Medical treatment of levodopa-induced dyskinesia. Ann. Neurol. 47, S179-S188 (2000).
29. Imbert, C., Bezard, E., Guitraud, S., Boraud, T. & Gross, C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J. Neurosci. Meth. 96, 71-76.
30. Bezard, E. et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-ridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861 (2001).
31. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch. Gen. Psychiatry 54, 225-232 (1997).
32. 2 receptor. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 225, 331-337 (1992).
33. 2 receptor using novel subtype-selective antagonists. Br. J. Pharmacol. 133, 1243-1248 (2001).